GlycoMira’s is developing a new class of glycosaminoglycan-based therapeutics that modulate the innate immune response and have the potential to address various unmet medical needs especially in cancer and respiratory diseases. These indications lack effective therapies that target the underlying molecular and cellular interactions causing the initiation and amplification of cyclic inflammatory signaling. GlycoMira's proprietary synthetic glycosaminoglycans and our lead candidate drug GM-1111 effectively reduce mucosal inflammations caused by various inducers, such as radiation, allergen, or microbial exposure. These are achieved by reducing cell death, pro-inflammatory cytokine production, and the influx of inflammatory cells.